- Open Access
PfMDR2 and PfMDR5 are dispensable for Plasmodium falciparum asexual parasite multiplication but change in vitro susceptibility to anti-malarial drugs
© van der Velden et al.; licensee BioMed Central. 2015
Received: 29 October 2014
Accepted: 25 January 2015
Published: 14 February 2015
Membrane-associated ATP binding cassette (ABC) transport proteins hydrolyze ATP in order to translocate a broad spectrum of substrates, from single ions to macromolecules across membranes. In humans, members from this transport family have been linked to drug resistance phenotypes, e.g., tumour resistance by enhanced export of chemotherapeutic agents from cancer cells due to gene amplifications or polymorphisms in multidrug resistance (MDR) protein 1. Similar mechanisms have linked the Plasmodium falciparum PfMDR1 transporter to anti-malarial drug resistance acquisition. In this study, the possible involvement of two related MDR proteins, PfMDR2 and PfMDR5, to emerging drug resistance is investigated by a reverse genetics approach.
A homologous double crossover strategy was used to generate P. falciparum parasites lacking the Pfmdr2 (PfΔmdr2) or Pfmdr5 (PfΔmdr5) gene. Plasmodium lactate dehydrogenase activity was used as read-out for sensitivity to artemisinin (ART), atovaquone (ATO), dihydroartemisinin (DHA), chloroquine (CQ), lumefantrine (LUM), mefloquine (MQ), and quinine (QN). Differences in half maximal inhibitory concentration (IC50) values between wild type and each mutant line were determined using a paired t-test.
Both PfΔmdr2 and PfΔmdr5 clones were capable of asexual multiplication. Upon drug exposure, PfΔmdr2 showed a marginally decreased sensitivity to ATO (IC50 of 1.2 nM to 1.8 nM), MQ (124 nM to 185 nM) and QN (40 nM to 70 nM), as compared to wild type (NF54) parasites. On the other hand, PfΔmdr5 showed slightly increased sensitivity to ART (IC50 of 26 nM to 19 nM).
Both Pfmdr2 and Pfmdr5 are dispensable for blood stage development while the deletion lines show altered sensitivity profiles to commonly used anti-malarial drugs. The findings show for the first time that next to PfMDR2, the PfMDR5 transport protein could play a role in emerging drug resistance.
ATP binding cassette (ABC) transporters are membrane-bound proteins that translocate a wide variety of substrates, including sugars, peptides, inorganic ions, proteins, and drugs across membranes by consumption of ATP, even against high concentration gradients [1,2]. These transport proteins either consist of two domains, a transmembrane domain with six membrane-spanning α-helices and a nucleotide-binding domain (half transporter) or four domains, two from each of the above alternating each other (full transporter). The nucleotide-binding domain is characteristic for ABC transport proteins and contains conserved Walker A and B motifs to bind ATP and an ABC signature sequence [3,4]. It is well described that the human P-glycoprotein, a member of the B subfamily of ABC transport proteins, also known as multidrug resistance (MDR) proteins, provides tumour resistance to chemotherapeutics by extrusion of these substances from cancer cells due to MDR1 gene amplifications or polymorphisms [2,5-7]. Based on sequence identity, Plasmodium falciparum has been shown to contain 16 ABC family members in its genome , some of which also play important roles in drug resistance development in this parasite.
Plasmodium falciparum causes the most dangerous type of malaria, a life-threatening disease that affected 198 million individuals with an estimated 584,000 fatalities in 2013, especially African children under five . Although treatable, recent reports showed emerging resistance as measured by prolonged parasite clearance times against artemisinin, the fast-acting drug in the first-line artemisinin-based combination therapy (ACT), on the Thai-Cambodian border and in Western Cambodia [10,11]. Whereas mutations in the K13-propeller have been identified as molecular markers for increased parasite half-life, additional loci involved in artemisinin resistance are yet to be discovered . Furthermore, amplification of and polymorphisms in the P. falciparum mdr1 and mrp1 genes have been associated with, e.g., artemisinin, chloroquine, lumefantrine, mefloquine, and quinine resistance [13-18]. In addition, polymorphisms and differential Asn-repeat lengths found in Pfmdr6 were shown to alter drug sensitivity to artesunate and piperaquine [19-22], while a single mutation in the heavy metal transporting PfMDR2  was linked to in vitro pyrimethamine resistance, which however, depended on dhfr mutation status . These findings show an important role for ABC transport proteins in P. falciparum drug resistance acquisition. Although the contribution of the MDR family in emerging drug resistance seems evident, as of yet no studies have assessed the effect of Pfmdr deletion lines on altered drug sensitivity.
Here, using a reverse genetics approach, both Pfmdr2 and Pfmdr5 were targeted for gene deletion. Subsequently, the involvement of two P. falciparum genes, Pfmdr2 and Pfmdr5, on drug sensitivity to seven well-established anti-malarial drugs, including artemisinin (ART), atovaquone (ATO), dihydroartemisinin (DHA), chloroquine (CQ), lumefantrine (LUM), mefloquine (MQ), and quinine (QN), belonging to four different drug classes (4-aminoquinolines, artemisinins, aryl-amino alcohols, and naphtoquinones), was studied .
Plasmodium falciparum wild type (NF54) and mutant lines PfΔmdr2 and PfΔmdr5 were cultured in a semi-automated system as described previously [26,27]. Briefly, parasites were grown in vitro in 5% haematocrit in RPMI medium supplemented with human serum (complete medium), which was changed twice daily. Human red blood cells were refreshed weekly and obtained from the Dutch national blood bank (Sanquin, Nijmegen).
Generation and genotyping of PfΔmdr2 and PfΔmdr5 parasites
Plasmodium falciparum mdr2 and mdr5 genes were stably deleted according to a homologous double crossover strategy [28,29]. Deletion constructs were based on the reported pHHT-FRT-(GFP)-Pf52 construct in which the homologous regions were replaced with mdr2 and mdr5 target regions (TRs), respectively . These regions were generated by amplifying P. falciparum NF54 genomic DNA (gDNA) using PfuUltra II Fusion HS DNA Polymerase (Bio-Connect B.V., Huissen, The Netherlands) with primers (P) P9 and P10 for the 5′ target region and primers P11 and P12 for the 3′ TR of mdr2, respectively. Similarly, primers P13-P16 were used to generate TRs for mdr5 (Additional file 1: Table S1). Following TOPO TA subcloning (Life Technologies Europe B.V., Bleiswijk, The Netherlands) of the amplified TRs, these were validated by restriction digestion and sequencing. Then, 5′ and 3′ TRs from each mdr gene were cloned in the pHHT-FRT-(GFP)-Pf52 construct using BssHII plus BsiWI and XmaI plus NheI restriction enzymes, respectively. This resulted in two deletion constructs, pHHT-FRT-(GFP)-Pfmdr2 and pHHT-FRT-(GFP)-Pfmdr5. Transfection and selection were performed as previously described , resulting in two mdr mutant lines. Both lines were subsequently transfected with the pMV-FLPe construct in order to excise heterologous DNA (hdhfr::gfp selectable marker) flanked by flippase recognition target (FRT) sites using enhanced flippase (FLPe) recombinase . Following limiting dilution, two cloned mutant lines, PfΔmdr2 and PfΔmdr5 were derived for downstream analysis.
Genotype analysis of the parasite mutants was performed using Expand Long Range dNTPack (Roche Diagnostics Nederland B.V., Almere, The Netherlands) (LR-PCR). Mixed asexual blood stage gDNA from wild type and deletion parasites was isolated using the QIAamp DNA Blood Mini Kit (Qiagen N.V., Venlo, The Netherlands). Primers P1 and P2 plus P5 and P6 (Additional file 1: Table S1) designed to flank the 5′ and 3′ TRs for mdr2 and mdr5, respectively, were used to analyse wild type and mutant DNA using LR-PCR for correct double homologous crossover integration. The LR-PCR started with an initial denaturation at 94°C for 5 min, followed by 35 cycles of denaturation at 94°C for 30 sec, annealing at 43.5-50°C (43.5°C for wild type and mutant mdr2, 46°C for wild type mdr5 and 50°C for mutant mdr5) for 30 sec, elongation at 60°C for 15 min  and a final elongation step at 62°C for 15 min. An additional intra-exonic PCR was performed on gDNA using primers P3 and P4 and P7 and P8 designed within the gene exon of both mdr genes (Additional file 1: Table S1). Briefly, gDNA from wild type and mutant lines was isolated as described above and amplified using Taq DNA polymerase (Life Technologies Europe B.V., Bleiswijk, The Netherlands). Denaturation at 94°C for 2 min was followed by 40 cycles of denaturation at 94°C for 15 sec, annealing at 52°C for 45 sec and elongation at 60°C for 30 sec, followed by a final elongation step at 60°C for 2 min.
Anti-malarial sensitivity assays
ART, ATO, CQ, DHA, LUM, MQ, and QN were all purchased from Sigma-Aldrich Chemie B.V. (Zwijndrecht, The Netherlands). ART and QN were dissolved in methanol, ATO, DHA, LUM, and MQ were dissolved in DMSO, CQ was dissolved in complete medium (described above) and serial dilutions of all drugs were stored at −20°C and thawed prior to use. Anti-malarial sensitivity assays were performed in at least three independent consecutive experiments using a slightly modified Plasmodium lactate dehydrogenase (pLDH) method as described previously . In short, 50 μL of serially diluted drugs was added to black, clear-bottom, 96-well, cell culture plates (Greiner Bio-One B.V., Alphen a/d Rijn, The Netherlands) in triplicate (duplicate for the 0 concentrations). Then, 50 μL mixed asexual stage wild type (NF54) and mutant parasites (2.5% parasitaemia in 1% final haematocrit) was added to each drug-containing well. Following incubation for 72 hrs at 37°C in a candle jar , the 96-well plates were frozen for at least 3 hrs at −20°C. After thawing the plates, parasite pLDH activity was measured by adding 70 μL of freshly made reaction mix (286 mM sodium L-lactate (Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands), 286 mM 3-acetyl pyridine adenine dinucleotide (Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands), 357.5 μM resazurin (Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands), 5.66 U/mL diaphorase (Worthington Biochemical Corp., Lakewood, NJ, USA), 1.4% Tween-20 (Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands), 20 mM Tris–HCl pH 8.0) to each well. Next, the plates were incubated in darkness for 30–60 min and absorbance was measured at 590 nm after excitation at 530 nm using a Synergy 2 Multi-Mode Microplate Reader (Bio-Tek, Bad Friedrichshall, Germany). The logarithm of half maximal inhibitory concentration (logIC50) values were determined by non-linear regression fitting of dose–response inhibition curves with variable slopes using GraphPad Prism version 5.03 (GraphPad Software, Inc., La Jolla, CA, USA). For each anti-malarial drug, Hill slopes were fixed to the average of all non-ambiguous slopes for each mdr mutant and their wild type control. Comparisons for significant differences between the obtained logIC50-values of wild type and mutant groups were carried out by a paired t-test. Finally, the plotted curves represent the combined averages of each individual anti-malarial assay per line, where the top of each curve fit was set to 100%.
Plasmodium falciparum mdr2 and mdr5 are dispensable for asexual blood stage multiplication
Both Pfmdr2 and Pfmdr5 modulate Plasmodium falciparum drug susceptibility
Increasing P. falciparum resistance to anti-malarial drugs is a major threat for effective malaria treatment. For this reason, it is important to unravel proteins and mechanisms that contribute to drug resistance. While involvement of the PfMDR1 transport protein in P. falciparum drug resistance is evident, little is known about contribution of other P. falciparum MDR members. Thus, using a reverse genetics approach, the aim of this study was to determine whether PfMDR2 and PfMDR5 could play a role in decreased drug sensitivity development using a panel of seven anti-malarials. Both PfΔmdr2 and PfΔmdr5 mutant lines were able to complete asexual development, highlighting that during this stage the transport proteins are dispensable for parasite viability. It is hypothesized that PfΔmdr2 and PfΔmdr5 become more susceptible to the tested anti-malarials if: i) the anti-malarial is a substrate for the wild type transporter; and, ii) the wild type MDR protein is located on the plasma membrane, which in the case of mutant lines would result in accumulation of the compounds within the parasite followed by its demise.
In contrast to the hypothesis above, deletion of P. falciparum mdr2 induced some decrease in sensitivity to the anti-malarials ATO, MQ and QN. As PfMDR2 has been reported to localize to the plasma membrane of the parasite , deleting this protein would result in accumulation of substrate anti-malarials within the parasite, leading to an increased sensitivity phenotype. However, besides plasma membrane association, PfMDR2 expression on the food vacuole has also been proposed [23,35]. MQ and QN are incorporated into growing haemozoin polymers within the food vacuole  and therefore are toxic to the parasite, hence, deletion of PfMDR2 might prevent accumulation of these drugs in the digestive vacuole, resulting in decreased sensitivity of PfΔmdr2 to MQ and QN as shown here. In contradiction to these results, it has been reported that MQ and potentially QN prevent uptake of host cell hemoglobin by inhibiting endocytosis [37,38] and therefore it may be advantageous for P. falciparum to sequester these drugs in the food vacuole . However, at this stage, it is unclear whether MQ and QN accumulation in the food vacuole is indeed affected by Pfmdr2 deletion. While LUM belongs to the same drug class as MQ and QN , the PfΔmdr2 mutant does not show the same trend in sensitivity to LUM as compared to the latter drugs. This might indicate that LUM is not a substrate for Pfmdr2 or (less likely) it has a different site of action, which currently is undetermined. ATO exerts its anti-malarial activity by inhibiting the parasite’s oxygen consumption in mitochondria . While mitochondrial localization of PfMDR2 has not been shown, further research may link PfMDR2 deletion to decreased ATO sensitivity. Moreover, it would be interesting to test several drug combinations to observe synergistic effects. These findings indicate that PfMDR2 may be involved in drug sensitivity either directly or indirectly via drug substrates.
Upon deletion of P. falciparum mdr5, only sensitivity to ART was altered. In concordance with the hypothesis, parasites lacking PfMDR5 became slightly more sensitive to ART, suggesting that this drug is a possible substrate for the PfMDR5 transport protein. As PfMDR5 has previously been shown to localize to the parasite’s plasma membrane , lacking this transport protein could lead to an accumulation of ART in the parasite, hence, resulting in increased sensitivity. On the contrary, there was no difference in sensitivity for PfΔmdr5 versus wild type parasites to DHA, the active metabolite of artemisinin derivatives , highlighting a possible subtle difference in substrate specificity.
Plasmodium falciparum does not require PfMDR2 and PfMDR5 to progress through the asexual multiplication cycle. Additionally, deletion of PfMDR2 resulted in a minor decreased sensitivity phenotype to ATO, MQ and QN. Therefore, P. falciparum might increase its resistance to these anti-malarials by modulating PfMDR2 in order to prevent these drugs from reaching their proposed target sites. Moreover, the PfMDR5 deletion mutant became slightly more sensitive upon exposure to ART, suggesting that over-expression or enhanced activity of this protein might contribute to ART resistance.
The work of MV is supported by a personal grant from Radboudumc.
- Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 1992;8:67–113.View ArticlePubMedGoogle Scholar
- Rees DC, Johnson E, Lewinson O. ABC transporters: the power to change. Nat Rev Mol Cell Biol. 2009;10:218–27.View ArticlePubMed CentralPubMedGoogle Scholar
- Walker JE, Saraste M, Runswick MJ, Gay NJ. Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J. 1982;1:945–51.PubMed CentralPubMedGoogle Scholar
- Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce SR, et al. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature. 1990;346:362–5.View ArticlePubMedGoogle Scholar
- Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. Genetic analysis of the multidrug transporter. Annu Rev Genet. 1995;29:607–49.View ArticlePubMedGoogle Scholar
- Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev. 1996;6:610–7.View ArticlePubMedGoogle Scholar
- Ling V, Gerlach J, Kartner N. Multidrug resistance. Breast Cancer Res Treat. 1984;4:89–94.View ArticlePubMedGoogle Scholar
- Koenderink JB, Kavishe RA, Rijpma SR, Russel FG. The ABCs of multidrug resistance in malaria. Trends Parasitol. 2010;26:440–6.View ArticlePubMedGoogle Scholar
- WHO. Malaria Fact sheet N°94. Geneva: World Health Organization; 2014.Google Scholar
- Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67.View ArticlePubMed CentralPubMedGoogle Scholar
- Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 2012;12:851–8.View ArticlePubMed CentralPubMedGoogle Scholar
- Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5.View ArticlePubMedGoogle Scholar
- Foote SJ, Thompson JK, Cowman AF, Kemp DJ. Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell. 1989;57:921–30.View ArticlePubMedGoogle Scholar
- Peel SA, Bright P, Yount B, Handy J, Baric RS. A strong association between mefloquine and halofantrine resistance and amplification, overexpression, and mutation in the P-glycoprotein gene homolog (pfmdr) of Plasmodium falciparum in vitro. Am J Trop Med Hyg. 1994;51:648–58.PubMedGoogle Scholar
- Raj DK, Mu J, Jiang H, Kabat J, Singh S, Sullivan M, et al. Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione. J Biol Chem. 2009;284:7687–96.View ArticlePubMed CentralPubMedGoogle Scholar
- Veiga MI, Ferreira PE, Jornhagen L, Malmberg M, Kone A, Schmidt BA, et al. Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance. PLoS One. 2011;6:e20212.View ArticlePubMed CentralPubMedGoogle Scholar
- Hao M, Jia D, Li Q, He Y, Yuan L, Xu S, et al. In vitro sensitivities of Plasmodium falciparum isolates from the China-Myanmar border to piperaquine and association with polymorphisms in candidate genes. Antimicrob Agents Chemother. 2013;57:1723–9.View ArticlePubMed CentralPubMedGoogle Scholar
- Phompradit P, Muhamad P, Wisedpanichkij R, Chaijaroenkul W, Na-Bangchang K. Four years’ monitoring of in vitro sensitivity and candidate molecular markers of resistance of Plasmodium falciparum to artesunate-mefloquine combination in the Thai-Myanmar border. Malar J. 2014;13:23.View ArticlePubMed CentralPubMedGoogle Scholar
- Mu J, Ferdig MT, Feng X, Joy DA, Duan J, Furuya T, et al. Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol Microbiol. 2003;49:977–89.View ArticlePubMedGoogle Scholar
- Anderson TJ, Nair S, Qin H, Singlam S, Brockman A, Paiphun L, et al. Are transporter genes other than the chloroquine resistance locus (pfcrt) and multidrug resistance gene (pfmdr) associated with antimalarial drug resistance? Antimicrob Agents Chemother. 2005;49:2180–8.View ArticlePubMed CentralPubMedGoogle Scholar
- Okombo J, Abdi AI, Kiara SM, Mwai L, Pole L, Sutherland CJ, et al. Repeat polymorphisms in the low-complexity regions of Plasmodium falciparum ABC transporters and associations with in vitro antimalarial responses. Antimicrob Agents Chemother. 2013;57:6196–204.View ArticlePubMed CentralPubMedGoogle Scholar
- Wang Z, Parker D, Meng H, Wu L, Li J, Zhao Z, et al. In vitro sensitivity of Plasmodium falciparum from China-Myanmar border area to major ACT drugs and polymorphisms in potential target genes. PLoS One. 2012;7:e30927.View ArticlePubMed CentralPubMedGoogle Scholar
- Rosenberg E, Litus I, Schwarzfuchs N, Sinay R, Schlesinger P, Golenser J, et al. pfmdr2 confers heavy metal resistance to Plasmodium falciparum. J Biol Chem. 2006;281:27039–45.View ArticlePubMedGoogle Scholar
- Briolant S, Bogreau H, Gil M, Bouchiba H, Baret E, Amalvict R, et al. The F423Y mutation in the pfmdr2 gene and mutations N51I, C59R, and S108N in the pfdhfr gene are independently associated with pyrimethamine resistance in Plasmodium falciparum isolates. Antimicrob Agents Chemother. 2012;56:2750–2.View ArticlePubMed CentralPubMedGoogle Scholar
- Rosenthal PJ. The interplay between drug resistance and fitness in malaria parasites. Mol Microbiol. 2013;89:1025–38.View ArticlePubMed CentralPubMedGoogle Scholar
- Ifediba T, Vanderberg JP. Complete in vitro maturation of Plasmodium falciparum gametocytes. Nature. 1981;294:364–6.View ArticlePubMedGoogle Scholar
- Ponnudurai T, Lensen AH, Leeuwenberg AD, Meuwissen JH. Cultivation of fertile Plasmodium falciparum gametocytes in semi-automated systems. 1. Static cultures. Trans R Soc Trop Med Hyg. 1982;76:812–8.View ArticlePubMedGoogle Scholar
- Duraisingh MT, Triglia T, Cowman AF. Negative selection of Plasmodium falciparum reveals targeted gene deletion by double crossover recombination. Int J Parasitol. 2002;32:81–9.View ArticlePubMedGoogle Scholar
- Maier AG, Braks JA, Waters AP, Cowman AF. Negative selection using yeast cytosine deaminase/uracil phosphoribosyl transferase in Plasmodium falciparum for targeted gene deletion by double crossover recombination. Mol Biochem Parasitol. 2006;150:118–21.View ArticlePubMedGoogle Scholar
- van Schaijk BC, Vos MW, Janse CJ, Sauerwein RW, Khan SM. Removal of heterologous sequences from Plasmodium falciparum mutants using FLPe-recombinase. PLoS One. 2010;5:e15121.View ArticlePubMed CentralPubMedGoogle Scholar
- Su XZ, Wu Y, Sifri CD, Wellems TE. Reduced extension temperatures required for PCR amplification of extremely A + T-rich DNA. Nucleic Acids Res. 1996;24:1574–5.View ArticlePubMed CentralPubMedGoogle Scholar
- Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, et al. Thousands of chemical starting points for antimalarial lead identification. Nature. 2010;465:305–10.View ArticlePubMedGoogle Scholar
- Jensen JB, Trager W. Plasmodium falciparum in culture: use of outdated erthrocytes and description of the candle jar method. J Parasitol. 1977;63:883–6.View ArticlePubMedGoogle Scholar
- Rubio JP, Cowman AF. Plasmodium falciparum: the pfmdr2 protein is not overexpressed in chloroquine-resistant isolates of the malaria parasite. Exp Parasitol. 1994;79:137–47.View ArticlePubMedGoogle Scholar
- Zalis MG, Wilson CM, Zhang Y, Wirth DF. Characterization of the pfmdr2 gene for Plasmodium falciparum. Mol Biochem Parasitol. 1993;62:83–92.View ArticlePubMedGoogle Scholar
- Mungthin M, Bray PG, Ridley RG, Ward SA. Central role of hemoglobin degradation in mechanisms of action of 4-aminoquinolines, quinoline methanols, and phenanthrene methanols. Antimicrob Agents Chemother. 1998;42:2973–7.PubMed CentralPubMedGoogle Scholar
- Hoppe HC, van Schalkwyk DA, Wiehart UI, Meredith SA, Egan J, Weber BW. Antimalarial quinolines and artemisinin inhibit endocytosis in Plasmodium falciparum. Antimicrob Agents Chemother. 2004;48:2370–8.View ArticlePubMed CentralPubMedGoogle Scholar
- Famin O, Ginsburg H. Differential effects of 4-aminoquinoline-containing antimalarial drugs on hemoglobin digestion in Plasmodium falciparum-infected erythrocytes. Biochem Pharmacol. 2002;63:393–8.View ArticlePubMedGoogle Scholar
- Rohrbach P, Sanchez CP, Hayton K, Friedrich O, Patel J, Sidhu AB, et al. Genetic linkage of pfmdr1 with food vacuolar solute import in Plasmodium falciparum. EMBO J. 2006;25:3000–11.View ArticlePubMed CentralPubMedGoogle Scholar
- Murphy AD, Lang-Unnasch N. Alternative oxidase inhibitors potentiate the activity of atovaquone against Plasmodium falciparum. Antimicrob Agents Chemother. 1999;43:651–4.View ArticlePubMed CentralPubMedGoogle Scholar
- Kavishe RA, van den Heuvel JM, van de Vegte-Bolmer M, Luty AJ, Russel FG, Koenderink JB. Localization of the ATP-binding cassette (ABC) transport proteins PfMRP1, PfMRP2, and PfMDR5 at the Plasmodium falciparum plasma membrane. Malar J. 2009;8:205.View ArticlePubMed CentralPubMedGoogle Scholar
- Navaratnam V, Mansor SM, Sit NW, Grace J, Li Q, Olliaro P. Pharmacokinetics of artemisinin-type compounds. Clin Pharmacokinet. 2000;39:255–70.View ArticlePubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.